NCT06747234Completed
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients
Effect of Oat Bran Supplementation on Plasma Lipid, Selected Fecal Bacteria, and Short-chain Fatty Acids Receptors Gene Expression in Peripheral Blood Mononuclear Cells in Patients With Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
The development of atherosclerosis is significantly influenced by the interplay between lipid and inflammatory factors. Endotoxemia, defined as the presence of endotoxins, particularly lipopolysaccharides (LPS) derived from Gram-negative bacteria, in the bloodstream, is closely associated with low-grade inflammation. This chronic, systemic inflammatory response does not reach the severity of acute inflammation but can contribute to the development of atherosclerosis and cardiovascular disease (CVD). Lipopolysaccharide-binding protein (LBP) is a soluble acute-phase protein that binds to bacterial LPS. Elevated levels of LBP have been linked to increased low-grade inflammation, which further exacerbates chronic inflammation and metabolic dysregulation. Dietary fiber, such as oat bran, may have a role in mitigating the effects of endotoxemia and its associated inflammation. Furthermore, dietary fiber could play a role in improving plasma lipid profiles. The present study will investigate the effect of oat bran supplementation on cardiometabolic risk markers, LBP concentrations, selected fecal bacteria, and short-chain fatty acids receptors gene expression in peripheral blood mononuclear cells in patients with coronary artery disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 18 Dec 2024
- Start date
- 20 May 2025
- Primary completion date
- 18 Dec 2025
- Lead sponsor
- Shahid Beheshti University of Medical Sciences
- Diseases
- Coronary artery disease
- NCT number
- NCT06747234
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 20 May 2025 to the primary completion date, 18 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any alteration to the treatment plan, including changes in drug type or surgical intervention
Other illness
- End-stage renal disease
- Inflammatory bowel syndrome (IBD),
- Cancer undergoing chemotherapy or radiotherapy,
Other
- Recent glucocorticoid or antibiotic treatment,
Who the study is looking for
- Patients with a history of coronary heart disease who have recently undergone coronary angioplasty
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shahid Modaress Hospital Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
| Shahid Modarres Hospital Coordinator of this site? Confirm its status | Tehran | Iran | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.